CA Patent

CA3200998A1 — Methods of treating conditions related to the s1p1 receptor

Assigned to Arena Pharmaceuticals Inc · Expires 2022-05-12 · 4y expired

What this patent protects

Described herein are methods for treating atopic dermatitis that allows for the effective treatment of the disease with an interruption period if certain adverse events are observed. Additionally, described here are new methods of treating moderate to severe atopic dermatitis.

USPTO Abstract

Described herein are methods for treating atopic dermatitis that allows for the effective treatment of the disease with an interruption period if certain adverse events are observed. Additionally, described here are new methods of treating moderate to severe atopic dermatitis.

Drugs covered by this patent

Patent Metadata

Patent number
CA3200998A1
Jurisdiction
CA
Classification
—
Expires
2022-05-12
Drug substance claim
No
Drug product claim
No
Assignee
Arena Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.